Calico Will Develop Drugs for Neurodegenerative Disorders

NFL: 3 in 10 ex-players face Alzheimer's, dementia, other debilitating brain conditions
NFL: 3 in 10 ex-players face Alzheimer’s, dementia, other debilitating brain conditions
Google-backed Calico will license and develop drugs for neurodegenerative disorders after P7C3 compounds were shown to activate an enzyme crucial to cell function and survival.

Calico’s plans to tackle aging are finally taking shape thanks to an agreement with a Texas-based research program. The Google-backed biotechnology company announced it will license and develop potential drugs for neurodegenerative disorders caused by the aging and death of nerve cells after a study showed that P7C3 compounds activate a cellular enzyme involved in energy metabolism that is crucial to the functioning and survival of cells.

READ FULL ARTICLE Curated publisher From San Francisco Chronicle